{{Drugbox
| IUPAC_name = 5-(2-Fluorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one
| image = Desmethylflunitrazepam.svg

<!--Clinical data-->
| tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| legal_CA = Schedule IV
| legal_status =
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number_Ref =
| CAS_number = 2558-30-7
| ATC_prefix =
| ATC_suffix =
| PubChem = 520217
| ChemSpiderID = 453770
| ChEMBL = 87369
| UNII = 055XLQ0YQ6

<!--Chemical data-->
| C=15 | H=10 | F=1 | N=3 | O=3
| molecular_weight =
| melting_point =
| smiles = FC1=C(C=CC=C1)C2=NCC(NC3=C2C=C(C=C3)[N+](=O)[O-])=O
| StdInChI = 1S/C15H10FN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)
| StdInChIKey = KNGIGRDYBQPXKQ-UHFFFAOYSA-N
}}

'''Desmethylflunitrazepam''' (also known as '''norflunitrazepam''', '''Ro05-4435''' and '''fonazepam''') is a [[benzodiazepine]] that is a [[metabolite]] of [[flunitrazepam]]<ref>{{cite journal|first1=Ruud W.|last1=Busker|first2=Gerard M. J. Beijersbergen|last2=van Henegouwen|first3=Brigitta M. C.|last3=Kwee|first4=Jos H. M.|last4=Winkens|title=Photobinding of flunitrazepam and its major photo-decomposition product N-desmethylflunitrazepam|url=http://www.sciencedirect.com/science/article/pii/0378517387901451|journal=International Journal of Pharmaceutics|date=May 1987|pages=113–120|volume=36|issue=2–3|via=ScienceDirect|doi=10.1016/0378-5173(87)90145-1}}</ref><ref>{{cite journal|first1=Janet K|last1=Coller|first2=Andrew A|last2=Somogyi|first3=Felix|last3=Bochner|title=Quantification of flunitrazepam's oxidative metabolites, 3-hydroxyflunitrazepam and desmethylflunitrazepam, in hepatic microsomal incubations by high-performance liquid chromatography|url=http://www.sciencedirect.com/science/article/pii/S0378434798003831|journal=Journal of Chromatography B: Biomedical Sciences and Applications|date=20 November 1998|pages=87–92|volume=719|issue=1–2|via=ScienceDirect|doi=10.1016/S0378-4347(98)00383-1|pmid=9869368}}</ref><ref>{{cite journal|first1=Tansel|last1=Kilicarslan|first2=Robert L.|last2=Haining|first3=Allan E.|last3=Rettie|first4=Usanda|last4=Busto|title=Flunitrazepam Metabolism by Cytochrome P450s 2C19 and 3A4|url=http://dmd.aspetjournals.org/content/29/4/460.long|journal=Drug Metabolism and Disposition|date=1 April 2001|issn=1521-009X|pages=460–465|volume=29|issue=4|via=dmd.aspetjournals.org|first5=Rachel F.|last5=Tyndale|first6=Edward M.|last6=Sellers|pmid=11259331}}</ref> and has been sold online as a [[designer drug]].<ref>{{cite journal|first1=Bjoern|last1=Moosmann|first2=Philippe|last2=Bisel|first3=Florian|last3=Franz|first4=Laura M.|last4=Huppertz|title=Characterization and ''in vitro'' phase I microsomal metabolism of designer benzodiazepines – an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam, and nitrazolam|url=http://onlinelibrary.wiley.com/doi/10.1002/jms.3840/abstract|journal=Journal of Mass Spectrometry|date=2016|issn=1096-9888|volume=51|issue=|pages=1080–1089|via=Wiley Online Library|doi=10.1002/jms.3840|pmid=27535017|first5=Volker|last5=Auwärter}}</ref><ref>{{cite journal|first1=Maria|last1=Katselou|first2=Ioannis|last2=Papoutsis|first3=Panagiota|last3=Nikolaou|first4=Chara|last4=Spiliopoulou|title=Metabolites replace the parent drug in the drug arena. The cases of fonazepam and nifoxipam|url=https://link.springer.com/article/10.1007/s11419-016-0338-5|journal=Forensic Toxicology|date=2016|issn=1860-8973|doi=10.1007/s11419-016-0338-5|first5=Sotiris|last5=Athanaselis}}</ref> It has an [[IC50|IC<sub>50</sub>]] value of 1.499 nM for the [[GABAA receptor|GABA<sub>A</sub>]] receptor.<ref>{{cite journal|first1=Desmond J.|last1=Maddalena|first2=Graham A. R.|last2=Johnston|title=Prediction of Receptor Properties and Binding Affinity of Ligands to Benzodiazepine/GABA<sub>A</sub> Receptors Using Artificial Neural Networks|url=http://pubs.acs.org/doi/abs/10.1021/jm00004a017|journal=Journal of Medicinal Chemistry|date=February 1995|pages=715–724|volume=38|issue=4|doi=10.1021/jm00004a017|pmid=7861419}}</ref><ref>{{cite journal|first1=Sung-Sau|last1=So|first2=Martin|last2=Karplus|title=Genetic Neural Networks for Quantitative Structure−Activity Relationships: Improvements and Application of Benzodiazepine Affinity for Benzodiazepine/GABA<sub>A</sub> Receptors|url=http://pubs.acs.org/doi/abs/10.1021/jm960536o|journal=Journal of Medicinal Chemistry|date=20 December 1996|pages=5246–5256|volume=39|issue=26|doi=10.1021/jm960536o|pmid=8978853}}</ref>

==See also==
{{colbegin}}
* [[Nitrazolam]]
* [[Phenazepam]]
* [[List of benzodiazepine designer drugs]]
{{colend}}

==References==
{{reflist}}

{{Benzodiazepines}}
{{Hypnotics and sedatives}}
{{GABAAR PAMs}}
{{Glycinergics}}

[[Category:Designer drugs]]
[[Category:Fluoroarenes]]
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Glycine receptor antagonists]]
[[Category:Lactams]]
[[Category:Nitrobenzodiazepines]]


{{pharma-stub}}